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Background: Although the median age at diagnosis of non-small cell lung cancer
(NSCLC) is 70 years, a subset of patients with NSCLC present at a younger age
(<40 years). Little is known about the time-trends in incidence of NSCLC in the young,
their characteristics and outcomes.
Methods: The surveillance, epidemiology, and end results database was used to extract
NSCLC cases from 1978 to 2010. Yearly incidence rates in various age groups, race, site
of disease, histology, treatment patterns, and outcomes were assessed. We modeled
Kaplan–Meyer survival curves stratified by age of presentation.
Results: Young patients represented 0.6% of incident NSCLC from 1978 to 2010.
The incidence of young NSCLC declined significantly during this time-period. Young
NSCLCs had a higher proportion of women (51%), Asians or Pacific Islanders (14%),
adenocarcinoma histology (59%) and were more likely to present with distant metastases
(68%). The young had better all cause and lung cancer-specific survival than the older
patients (median survival for localized, regional, and distant disease: not reached, 28, 9
vs. 46, 17, 5months; p<0.001 for all groups). Male sex, non-adenocarcinoma histology,
and main bronchial primary were independent negative prognostic factors among the
young. In contrast to the overall population, black race was a poor prognostic factor
among the young.
Conclusion: The incidence of NSCLC in the young decreased from 1978 to 2010.
The clinical characteristics of NSCLC in the young, including demographic distribution,
treatment, and outcomes are different from those observed in the older patients.
Keywords: non-small cell lung cancer, SEER, young, population-based studies, disparities
Introduction
Lung cancer is the most common cause of cancer-related death in the United States and worldwide
(1, 2). Despite recent advances in treatment, prognosis of patients with lung cancer remains poor,
with 5-year overall survival of approximately 15% (3). Non-small cell lung cancer (NSCLC), which
accounts for over 85% of all lung cancer, is often considered a disease of the older population with a
median age at diagnosis of about 70 years (3).
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FIGURE 1 | Time-trends in incidence of NSCLC over time among
patients<40 years (A) and40 years (B) over 1975–2010.
However, a significant proportion of new NSCLC patients,
ranging between 1 and 10%, are younger than 40 years (4–
9). There are several issues, which are particularly relevant to
NSCLC in these patients, for example, their distinctive cancer
biology, treatment tolerance, adherence, effectiveness, fertility
preservation, and early death (10). Despite being an important
demographic subgroup, there are limited data on the incidence,
time-trends, and clinical characteristics of young patients with
lung cancer.
Although there are substantial variability in the age ranges
used in past studies, available data suggest that patients younger
than 40 have a higher incidence of adenocarcinoma and greater
representation of females (5, 7, 11–24). Reports comparing
stage at presentation and outcomes of NSCLC in the young to
older patients have yielded discordant results (11, 12, 14–16, 18,
20–22, 24).
Only two large population-based studies have studied lung
cancer in the young using the surveillance, epidemiology, and
end results (SEER) (5, 6). Since the recent report, there have been
significant advances in the screening, diagnosis, andmanagement
of NSCLC. Additional registries have been included in SEER
and the introduction of the normalized localized/regional/distant
staging system have made comparison across a longer period
more accurate compared with the American Joint Committee on
Cancer staging used in prior studies. Furthermore, the population
younger than 40 in itself is heterogeneous and previous stud-
ies have not explored clinicopathological features and outcomes
among the different age groups constituting this larger group. In
this study, using the normalized localized/regional/distant staging
system, we analyzed the SEER database for NSCLC patients from
TABLE 1 | Characteristics of NSCLC patients diagnosed between 1998 and
2010 by age group.
0–39 years >40 years p Value
Count Percentage Count Percentage
Total 2786 458; 217
Gender <0.0001
Men 1354 48:60% 253;324 55:28%
Women 1432 51:40% 204;893 44:72%
Race <0.0001
White 1938 69:56% 379;694 82:86%
Black 419 15:04% 51;337 11:20%
American-
Indian/Alaska
Native
18 0:65% 1837 0:40%
Asian or Pacific
Islander
401 14:39% 24;497 5:35%
Unknown 10 0:36% 852 0:19%
Histology <0.0001
Adenocarcinoma 1648 59:15% 194;374 42:42%
Squamous 284 10:19% 111;467 24:33%
Adenosquamous 45 1:62% 5;922 1:29%
Large cell 165 5:92% 20;055 4:38%
Carcinoma,
NOS
638 22:90% 125;701 27:43%
Undifferentiated 6 0:22% 698 0:15%
Staging <0.0001
In situ 0 0:00% 0 0:00%
Localized 274 9:83% 86;388 18:85%
Regional 490 17:59% 107;925 23:55%
Distant 1902 68:27% 237;815 51:90%
Unknown 120 4:31% 26;089 5:69%
Primary site <0.0001
Main bronchus 151 5:42% 19;593 4:28%
Upper lobe 1228 44:08% 229;961 50:19%
Middle lobe 139 4:99% 18;578 4:05%
Lower lobe 620 22:25% 113;176 24:70%
Overlapping
lesion of lung
61 2:19% 6;002 1:31%
Lung, NOS 587 21:07% 70;907 15:47%
1998 to 2010 and evaluated characteristics of patients younger
than 40. Using the data from 1975 to 2010, we also describe
time-trends in the incidence of NSCLC in this population.
Materials and Methods
SEER*Stat version 8.0.4 was used for all data collection and
frequency analysis. For frequency analysis, SEER 18 Register
Research Data+ Hurricane Katrina impacted Lousiana Cases,
November 2012 sub (2973–2010 varying), released April 2013
were used to evaluate demographic characteristics and treatment
received. Patient inclusion criteria are Site recode International
Classification of Diseases for Oncology, third Edition 2008 Lung
and Bronchus (old code C340–C349), and year of diagnosis
1998–2010, and NSCLC. NSCLC histology was categorized using
International Classification of Diseases for Oncology, third Edi-
tion histology codes formalignant caseswith the following groups:
adenocarcinoma (8140, 8141, 8143, 8147, 8250-8255, 8260, 8310,
8430, 8480, 8481, 8490, 8570, 8571, 8572, 8573, 8574), squamous
cell carcinoma (8052, 8070–8078), adenosquamous cell carci-
noma (8560), large cell carcinoma (8012, 8013), and carcinoma
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TABLE 2 | Characteristics by age groups for patients<40 years (diagnosed between 1998 and 2010).
15–19 years 20–24 years 25–29 years 30–34 years 35–39 years p Value
Count Percentage Count Percentage Count Percentage Count Percentage Count Percentage
Gender 0:8061
Male 10 45:45% 41 50:62% 101 50:75% 299 50:25% 895 47:89%
Female 12 54:55% 40 49:38% 98 49:25% 296 49:75% 974 52:11%
Race 0:0011
White 17 77:27% 64 79:01% 131 65:83% 388 65:21% 1325 70:89%
Black 4 18:18% 8 9:88% 22 11:06% 94 15:80% 289 15:46%
American-Indian/Alaska Native 0 0:00% 1 1:23% 0 0:00% 2 0:34% 14 0:75%
Asian or Pacific Islander 1 4:55% 7 8:64% 46 23:12% 107 17:98% 236 12:63%
Unknown 0 0:00% 1 1:23% 0 0:00% 4 0:67% 5 0:27%
Histology
Adenocarcinoma 16 72:73% 52 64:20% 121 60:80% 384 64:54% 1058 56:61% 0:021
Squamous cell carcinoma 4 18:18% 15 18:52% 21 10:55% 48 8:07% 195 10:43%
Adenosquamous 0 0:00% 0 0:00% 4 2:01% 9 1:51% 32 1:71%
Large cell carcinoma 0 0:00% 3 3:70% 13 6:53% 25 4:20% 124 6:63%
Carcinoma, NOS 2 9:09% 11 13:58% 39 19:60% 129 21:68% 456 24:40%
Undifferentiated 0 0:00% 0 0:00% 1 0:50% 0 0:00% 4 0:21%
Staging
In situ 0 0 0 0 0 0 0 0 0 0 <0:0001
Localized 10 45:45% 20 24:69% 25 12:56% 59 9:92% 155 8:29%
Regional 2 9:09% 13 16:05% 27 12:56% 94 15:80% 348 12:13%
Distant 10 45:45% 42 51:85% 134 67:34% 415 69:75% 1293 45:07%
Unknown/unstaged 0 0:00% 6 7:41% 13 6:53% 27 4:54% 73 2:54%
Primary site
Main bronchus 1 4:55% 9 11:11% 9 4:52% 29 4:87% 98 5:24% <0:0001
Upper lobe 8 36:36% 18 22:22% 56 28:14% 242 40:67% 901 48:21%
Middle lobe 3 13:64% 9 11:11% 9 4:52% 35 5:88% 81 4:33%
Lower lobe 7 31:82% 20 24:69% 54 27:14% 147 24:71% 387 20:71%
Overlapping lesion of lung 1 4:55% 5 6:17% 8 4:02% 12 2:02% 34 1:82%
Lung, NOS 2 9:09% 20 24:69% 63 31:66% 130 21:85% 368 19:69%
Number of primaries 0:7131
One primary only 21 95:45% 74 91:36% 182 91:46% 529 88:91% 1674 89:57%
Multiple primaries 1 4:55% 7 8:64% 17 8:54% 66 11:09% 195 10:43%
not otherwise specified (NOS) (8010, 8046, 8050, 8051, 8575),
undifferentiated (8020). Only malignant behavior, known age,
case in research database cases was selected. Statistical homogene-
ity of the frequency distributionswas examined usingChi-squared
tests.
For survival time analysis, the same data registry and selec-
tion criteria were applied. Five-year survival rate and median
survival for each patient subgroup were calculated using SEER
STAT and R. 354,513 individual records were collected to gen-
erate Kaplan–Meier curves as well as hazard ratio (HR) esti-
mates based on Cox proportional hazard models adjusted for
multiple covariates (multivariate analysis) or each single covari-
ates of concern (Univariate analysis). Kaplan–Meier curves were
plotted using GraphPad Prism 6.0. Cox model fitting was done
using R.
For analysis on the incidence and its trend, we used data from
all nine registries covering 1975–2010. The estimated incidence
rates were adjusted for patient age. Percentage change, annual
percentage change were reported using SEERT STAT based on
themethod described previously (25) withmodification for confi-
dence intervals (CIs). Percentage change was calculated using data
collected at 1-year intervals. APC was calculated using weighted
least squares. Comparison of the incidence observed from two
periods of 1975–1982 and 1983–2010 were reported.
Results
Time-Trends in Incidence of NSCLC in the Young
Figure 1A shows the time-trends in incidence of NSCLC in
patients younger than 40 from 1975 to 2010. The incidence of
NSCLC decreased in the young during this period: 1.1/100,000 in
1975 vs. 0.4/100, 000 in 2010 in males and 0.9/100,000 in 1975 vs.
0.4/100, 000 in 2010 in females. The annual percentage change in
period 1983–2010 was statistically significant. Although NSCLC
incidence in older males (over 40 years old) has declined over the
same period (164.9/100, 000 in 1975 vs. 121.8/100,000 in 2010),
the incidence in older females has increased (44.4/100,000 in 1975
vs. 86/100, 000 in 2010) (Figure 1B).
Characteristics of NSCLC in the Young
Table 1 shows the characteristics of NSCLC in patients younger
than 40 compared with older patients. NSCLC still overwhelm-
ingly remains a disease of older individuals: 99.4% of incident
NSCLC in the United States between 1998 and 2010 were in
patients older than 40. However, the male-predominant distribu-
tion of NSCLC in adults was compromised in the young among
whom women had a statistically non-significantly higher inci-
dence of NSCLC than men (51 vs. 49%; p= 0.14). Asians or
Pacific Islanders accounted for 14%of youngNSCLCwhereas they
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FIGURE 2 |Median survival of patients<40 years and40 years with
localized (A), regional (B), and distant (C) NSCLC.
accounted for only 5% among the older population. Although less
marked, the frequency of Blacks was higher among those younger
than 40 (15 vs. 11%). Adenocarcinoma and squamous cell lung
cancer were the most common histologies among the young. The
young had a higher frequency of adenocarcinoma (59 vs. 42%)
and lower frequency of squamous lung cancers (10 vs. 24%) than
the older population. Distant metastases at diagnosis were more
common among the young (68 vs. 52%). Upper lobe cancers,
which are thought to be associated with cigarette smoking, were
less common among the young (44 vs. 50%). Thus, significant
differences in frequency were observed in the young compared
with older patients in terms of gender, race, histology, distant
metastasis, and primary site of NSCLC.
Although age by itself is not a major determinant of treatment
for NSCLC, co-morbiditiesmay limit the ability to deliver therapy.
SEER does not provide sufficient data to estimate all treatment,
but has information on cancer-directed surgeries. For all stages,
the young were significantly more likely to undergo surgery than
older patients (p= 0.0054 to<0.0001) (data not shown).
To better understand the clinicopathological characteristics of
the young, we assessed them in 5-year age increments starting
from age 15 (Table 2). Although individual age subgroups had
limited number of patients, the results show significant differences
TABLE 3 | Lung cancer specific survival for patients under and over 40.
5-year survival (%)* CI 95% p Value
Localized <0.001
<40 91.2 88.7–93.2
40 55.9 55.4–56.3
Regional <0.001
<40 50.7 46.6–54.6
40 26.7 26.3–27.0
Distant <0.001
<40 9.7 8.2–11.3
40 4.2 4.1–4.3
*Cause-specific survival: non-lung cancer death counted as alive/sensored.
in race, histology, stage at diagnosis, and primary site of involve-
ment between the individual age groups.
Outcomes of NSCLC in the Young
Using the standardized localized/regional/distant staging system,
stage-for-stage, the young had superior overall survival than the
older population. The differences in survival were more marked
for localized and regional disease than for distant disease. Median
survival of older population with localized disease was 46months
compared with the young for whom median survival was not
reached (HR, 1.29; 95% CI 1.39–1.54; p< 0.001) (Figure 2A).
Patients younger and older than 40 with regional disease had
median survival of 28 and 17months, respectively (HR, 2.96;
95% CI 2.29–3.82; p< 0.001) (Figure 2B). Median survival of the
young and older patients with distant disease was 9 and 5months,
respectively (HR, 1.53; 95% CI 1.36–1.73; p< 0.001) (Figure 2C).
The young also had a lower lung cancer-specific death rate than
their older counter parts. The 5-year lung cancer specific survival
for under 40 vs. over 40 age groups were 91.2 vs. 55.9% for
localized, 50.7 vs. 26.7% for regional, 9.7 vs. 4.2% at distant stage
(Table 3).
Based on the Cox proportional hazard model adjusted for mul-
tiple covariates, the risk of death was higher for those older than
40 (HR, 1.45; 95% CI, 1.39–1.52; p< 0.001). Other independent
negative prognostic factors included male sex (HR, 1.16; 95% CI,
1.15–1.17; p< 0.001), non-adenocarcinoma histology, and loca-
tion of primary tumor in themain bronchus,middle lobe, or upper
lobe. Favorable prognostic factors included Asian/Pacific Islander
(HR, 0.78; 95% CI, 0.765–0.790; p< 0.001) or Black race (HR
0.98; 95% CI 0.969–0.991; p= 0.0004), localized (HR, 0.38; 95%
CI 0.378–0.388; p< 0.001), or regional disease (HR, 0.54; 95% CI
0.536–0.547; p< 0.001), upper lobe primary, surgical resection,
and year of diagnosis 2004–2010 compared with 1998–2003.
Among those younger than 40 (Table 4), the risk of death
was higher for males compared with females (11 vs. 15months;
HR, 1.174; 95% CI, 1.071–1.285; p< 0.001). As in the over-
all population, Asian/Pacific Islander race was an independent
positive prognostic factor (HR, 0.831; 95% CI 0.727–0.950). In
contrast to the overall population, Black race was a poor prog-
nostic factor among the young (HR, 1.22; 95% CI, 1.075–1.384;
p< 0.001). Independent negative prognostic factors included
non-adenocarcinoma histology and main bronchial primary (HR
1.23; 95%CI, 1.009–1.507). Surgical resection (HR, 0.497; 95%CI,
0.434–0.570) and the year of diagnosis 2004–2010 compared with
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TABLE 4 |Multivariate analysis to examine potential factors associated with survival in the young.
N Median
survival
1-year survival
rate (95% CI)
5-year survival
rate (95% CI)
HR (univariate
analysis)
p Value HR
(multivariate)
p Value
Gender
Men 1271 11 43.9 (41.2, 46.8) 18.0 (15.8, 20.6) 1.22 (1.115, 1.335) 1.56E-05 1.174 (1.071, 1.285) 0.000566
Women 1276 15 54.9 (52.1, 57.7) 21.2 (18.8, 23.8) 1 1
Race
White 1759 12 49.3 (46.9, 51.7) 20.7 (18.7, 22.9) 1 1
Black 383 10 41.8 (37.1, 47.2) 15.5 (12.0, 20.0) 1.193 (1.054, 1.351) 0.005 1.220 (1.075, 1.384) 0.00199
American-Indian/Alaska Native 17 8 41.2 (23.3, 72.7) 29.4 (14.1, 61.4) 0.947 (0.536, 1.672) 0.852 1.214 (0.684, 2.154) 0.508
Asian or Pacific Islander 378 15 57.6 (52.7, 63.0) 15.8 (11.8, 21.3) 0.950 (0.833, 1.084) 0.446 0.831 (0.727, 0.950) 0.0065
Unknown 10 N/A N/A: only 2 events N/A 0.178 (0.045, 0.713) 0.015 0.245 (0.061, 0.986) 0.0477
Histology
Adenocarcinoma 1524 15 55.0 (52.5, 57.7) 21.3 (19.0, 23.8) 1 1
Squamous 244 12 47.8 (41.8, 54.7) 22.5 (17.5, 28.9) 1.065 (0.911, 1.246) 0.428 1.144 (0.973, 1.345) 0.1028
Adenosquamous 41 10 49.0 (35.5, 67.5) 12.9 (5.69, 29.2) 1.306 (0.929, 1.838) 0.125 1.833 (1.299, 2.589) 0.000572
Large cell 154 9 34.3 (27.5, 42.8) 13.2 (8.64, 20.2) 1.398 (1.166, 1.678) 0.0003 1.332 (1.107, 1.603) 0.00243
Carcinoma, NOS 579 9 39.9 (36.0, 44.1) 16.4 (13.4, 20.0) 1.356 (1.216, 1.513) 4.56e-08 1.123 (1.003, 1.258) 0.0446
Undifferentiated 5 4 40.0 (13.67, 1) N/A 2.528 (1.050, 6.087) 0.039 1.793 (0.742, 4.336) 0.1949
Staging
Localized 237 >114 92.9 (89.6, 96.3) 74.8 (69.6, 81.5) 0.114 (0.088, 0.148) <2e-16 0.190 (0.144, 0.252) <2e-16
Regional 434 28 73.5 (69.4, 77.9) 34.2 (29.6, 39.5) 0.369 (0.323, 0.422) <2e-16 0.496 (0.427, 0.576) <2e-16
Distant 1777 9 37.2 (34.9, 39.6) 7.53 (6.20, 9.15) 1 1
Unknown 99 17 59.0 (49.9, 69.8) 35.4 (26.6, 47.2) 0.439 (0.340, 0.569) 3.92E-10 0.368 (0.281, 0.481) 2.38e-13
Primary site
Main bronchus 142 8 29.3 (22.6, 38.0) 18.1 (12.5, 26.4) 1.477 (1.215, 1.797) 9.43E-05 1.233 (1.009, 1.507) 0.0411
Upper lobe 1130 13 51.3 (48.4, 54.4) 21.6 (19.1, 24.4) 1 1
Middle lobe 129 18 62.7 (54.7, 71.9) 21.7 (15.1, 31.4) 0.862 (0.695, 1.067) 0.173 0.965 (0.778, 1.196) 0.7423
Lower lobe 564 16 56.4 (52.4, 60.8) 21.7 (18.0, 26.0) 0.899 (0.797, 1.013) 0.081 0.922 (0.817, 1.041) 0.1902
Overlapping lesion of lung 52 14 53.1 (40.3, 69.8) 19.4 (10.3, 36.9) 1.040 (0.745, 1.452) 0.817 0.968 (0.692, 1.353) 0.8489
Lung, NOS 530 10 39.8 (35.7, 44.4) 12.9 (10.0, 16.7) 1.342 (1.194, 1.509) 8.41E-07 0.999 (0.886, 1.128) 0.994
Surgery performed or not
Yes 729 46 77.2 (74.1, 80.3) 45.1 (41.3, 49.3) 0.301 (0.268, 0.338) <2e-16 0.497 (0.434, 0.570) <2e-16
No 1779 9 37.9 (35.6, 40.3) 8.45 (7.05, 10.12) 1 1
Unknown 39 10 46.2 (32.3, 66.0) 24.6 (13.5, 44.8) 0.624 (0.423, 0.920) 0.0171 0.986 (0.664, 1.463) 0.943
Year of diagnosis
1998–2004 1416 11 45.1 (42.6, 47.8) 17.6 (15.7, 19.8) 1 1
2004–2010 1131 15 55.4 (52.4, 58.5) 22.2 (19.1, 25.9) 0.822 (0.748, 0.902) 4.08E-05 0.746 (0.678, 0.821) 2.16E-09
1998–2003 (HR, 0.746; 95% CI 0.678–0.821) were other favorable
prognostic factors.
Discussion
Non-small cell lung cancer overwhelmingly remains a disease of
the older population. A smaller, but not insignificant proportion
of patients with NSCLC are younger than 40. The epidemiology
of NSCLC in the young and their clinical characteristics are not
well defined. Based on these considerations, we used the SEER
database to conduct a large population-based study of NSCLC
in the young. Our aims were to evaluate the time-trends in inci-
dence, clinicopathologic characteristics, and prognostic factors of
NSCLC in the young.
Young patients represented 0.6% of incident NSCLC from 1978
to 2010. The incidence of young NSCLC declined significantly
during this time. Young NSCLCs had a higher proportion of
women, Asians or Pacific Islanders, adenocarcinoma histology
and were more likely to present with distant metastases at diagno-
sis than the older population. The young were less likely to have
upper lobe cancers.
Although for purposes of observational studies, patients
younger than 40 are grouped into one category, we found that this
group in itself was heterogeneous in terms of clinical and patho-
logical characteristics. Within the young population, significant
differences were observed in the frequency of race, histology, stage
at diagnosis, and primary site of involvement. Using the standard-
ized localized/regional/distant staging system, stage-for-stage, the
young had better all cause and lung cancer-specific survival than
the older population. Multivariate Cox model analyses identified
male sex, non-adenocarcinoma histology, and main bronchial
primary as independent negative prognostic factors among the
young. Additionally, in contrast to the overall population, black
race was a poor prognostic factor among the young.
Our results extend upon those from prior population-based
registry studies, which showed a higher proportion of women,
adenocarcinoma, and metastatic disease in the young (5, 6). As in
our study, both prior studies found somewhat modest increases in
the overall magnitude of risk of death. In addition to the previous
studies, we show a decrease in the incidence of NSCLC from
1975 to 2010 and demonstrate significant differences in age-based
subgroups among those younger than 40.
Cancer rates in the young are thought to be a useful indi-
cator to assess the impact of recent cancer control efforts.
Using population-based registries with state-specific data, Jemal
et al. have demonstrated that lung cancer death rates in young
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adults aged between 30 and 39 years correlated strongly and
inversely with the individual state tobacco control efforts (26).
The observed decline in the NSCLC death rates among the young
in our study could therefore be attributed in part to the past
anti-smoking interventions (27).
Our finding of a comparable incidence of NSCLC amongmales
and females in the young indicates the effect of factors other
than cigarette smoking. This is in contrast to older population
wherein smoking is the major risk factor for lung cancer. In them,
the convergence of relative risks of NSCLC for men and women
have been attributable to the convergence of smoking patterns
amongmen andwomen since 1960s and the aging of birth cohorts
with the heaviest lifetime history of smoking (28). Despite a
probable early start of smoking in young adults with lung cancer,
the development of the disease cannot be fully explained due
to smoking alone. Several studies have indicated higher genetic
susceptibility among younger patients (29–31), aswell as influence
of occupational risk factors (32). There are limited data on the
genetic basis of lung cancer susceptibility (33). Recent studies have
reported that germline mutations in EGFR and HER2 genes can
predispose the development of lung cancer (34, 35).
Wewere unable to clarify the incidence of smoking in the young
NSCLC since smoking status is not captured in the SEER database.
Nevertheless, a growing body of literature suggests that NSCLC
in never-smokers has several distinct clinical, pathological, and
molecular characteristics implying that it might be a different
disease compared with NSCLC in smokers (36); adenocarcinoma
is the most frequent histology in never-smokers and alterations in
driver oncogenes such as EGFR, and ALK are more common in
tumors from never-smokers compared to smokers.
Although based on a relatively small number of patients, our
findings indicate that black race was a poor prognostic factor
among the young. Whether this disparity is related to genetic dif-
ferences in the tumor, pharmacogenomics, or differential access
to care will need additional study. Previous studies have sug-
gested that patients with upper lobe tumors tend to have had
more exposure to tobacco. In our study, upper lobe cancers were
less common among the young, further supporting the notion
that genetic susceptibility and other environmental factors may
be important risk factors in the pathogenesis of NSCLC in the
young (37).
This study provides the most comprehensive analyses to date
of a large registry dataset of young NSCLC. We observed sig-
nificant differences in clinical presentation even among those
younger than 40. Further studies are needed to understand the
interaction between genetic susceptibility and environmental car-
cinogens including tobacco in the pathogenesis of NSCLC in the
young.
Author Contributions
AT, YC, MJ, and GG designed the work. YC and TY performed
the data acquisition and analysis. AT, YC, MJ, TY, and GG did
the interpretation. AT, YC, and MJ drafted the manuscript. All
authors approved the final version of the manuscript.
Acknowledgments
This research was supported by the Intramural Research Program
of the National Institutes of Health.
References
1. Goldstraw P, Crowley J, Chansky K, GirouxDJ, Groome PA, Rami-Porta R, et al.
The IASLC lung cancer staging project: proposals for the revision of the TNM
stage groupings in the forthcoming (seventh) edition of the TNM classification
of malignant tumours. J Thorac Oncol (2007) 2(8):706–14. doi:10.1097/JTO.
0b013e31812f3c1a
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin
(2012) 62(1):10–29. doi:10.3322/caac.20138
3. Howlader NNA, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010.
Bethesda, MD: National Cancer Institute (2013). Available from: http://seer.
cancer.gov/csr/1975_2010/
4. DeCaro L, Benfield JR. Lung cancer in young persons. J Thorac Cardiovasc Surg
(1982) 83(3):372–6.
5. Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccir-
illo J, et al. Distinctive characteristics of non-small cell lung cancer (NSCLC)
in the young: a surveillance, epidemiology, and end results (SEER) analysis. J
Thorac Oncol (2010) 5(1):23–8. doi:10.1097/JTO.0b013e3181c41e8d
6. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer
in young patients: analysis of a surveillance, epidemiology, and end results
database. J Clin Oncol (1998) 16(2):651–7.
7. Jubelirer SJ, Wilson RA. Lung cancer in patients younger than 40 years
of age. Cancer (1991) 67(5):1436–8. doi:10.1002/1097-0142(19910301)67:
5<1436::AID-CNCR2820670528>3.0.CO;2-2
8. RochaMP, Fraire AE, Guntupalli KK, Greenberg SD. Lung cancer in the young.
Cancer Detect Prev (1994) 18(5):349–55.
9. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR.
Non-small cell lung cancer at the extremes of age: impact on diagnosis and
treatment. Ann Thorac Surg (1997) 63(1):193–7. doi:10.1016/S0003-4975(96)
00745-X
10. Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology:
an emerging field. J Clin Oncol (2010) 28(32):4781–2. doi:10.1200/JCO.2010.
30.5128
11. Liam CK, Lim KH, Wong CM. Lung cancer in patients younger than 40 years
in a multiracial Asian country. Respirology (2000) 5(4):355–61. doi:10.1046/j.
1440-1843.2000.00275.x
12. Maruyama R, Yoshino I, Yohena T, Uehara T, Kanematsu T, Kitajima M, et al.
Lung cancer in patients younger than 40 years of age. J Surg Oncol (2001)
77(3):208–12. doi:10.1002/jso.1096
13. Mizushima Y, Yokoyama A, Ito M, Manabe H, Hirai T, Minami H,
et al. Lung carcinoma in patients age younger than 30 years. Can-
cer (1999) 85(8):1730–3. doi:10.1002/(SICI)1097-0142(19990415)85:8<1730::
AID-CNCR12>3.0.CO;2-G
14. Sekine I, Nishiwaki Y, Yokose T, Nagai K, Suzuki K, Kodama T. Young lung
cancer patients in Japan: different characteristics between the sexes.Ann Thorac
Surg (1999) 67(5):1451–5. doi:10.1016/S0003-4975(99)00171-X
15. Shimono T, Hayashi T, Kimura M, Yada I, Namikawa S, Yuasa H, et al. Surgical
treatment of primary lung cancer in patients less than 40 years of age. J Clin
Oncol (1994) 12(5):981–5.
16. Icard P, Regnard JF, de Napoli S, Rojas-Miranda A, Dartevelle P, Levasseur P.
Primary lung cancer in young patients: a study of 82 surgically treated patients.
Ann Thorac Surg (1992) 54(1):99–103. doi:10.1016/0003-4975(92)91150-8
17. Ganz PA, Vernon SE, Preston D, CoulsonWF. Lung cancer in younger patients.
West J Med (1980) 133(5):373–8.
18. Pemberton JH, Nagorney DM, Gilmore JC, Taylor WF, Bernatz PE.
Bronchogenic-carcinoma in patients younger than 40 years. Ann Thorac
Surg (1983) 36(5):509–15. doi:10.1016/S0003-4975(10)60678-9
19. Mauri D, Pentheroudakis G, BafaloukosD, PectasidesD, Samantas E, Efstathiou
E, et al. Non-small cell lung cancer in the young: a retrospective analysis of diag-
nosis, management and outcome data. Anticancer Res (2006) 26(4B):3175–81.
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 1136
Thomas et al. NSCLC in young
20. Bryant AS, Cerfolio RJ. Differences in outcomes between younger and older
patients with non-small cell lung cancer.Ann Thorac Surg (2008) 85(5):1735–9.
doi:10.1016/j.athoracsur.2008.01.031
21. Lienert T, Serke M, Schonfeld N, Loddenkemper R. Lung cancer in
young females. Eur Respir J (2000) 16(5):986–90. doi:10.1183/09031936.00.
16598600
22. BourkeW, Milstein D, Giura R, Donghi M, Luisetti M, Rubin AHE, et al. Lung-
cancer in young-adults. Chest (1992) 102(6):1723–9. doi:10.1378/chest.102.6.
1723
23. Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, et al. Advanced non-small
cell lung cancer in patients aged 45 years or younger: outcomes and prognostic
factors. BMC Cancer (2012) 12:241. doi:10.1186/1471-2407-12-241
24. Roviaro GC, Varoli F, Zannini P, Fascianella A, Pezzuoli G. Lung-cancer in the
young. Chest (1985) 87(4):456–9. doi:10.1378/chest.87.4.456
25. Li Y, Tiwari RC, Zou ZH. An age-stratified Poisson model for comparing
trends in cancer rates across overlapping regions. Biom J (2008) 50(4):608–19.
doi:10.1002/bimj.200710430
26. Jemal A, Cokkinides VE, Shafey O, Thun MJ. Lung cancer trends in young
adults: an early indicator of progress in tobacco control (United States). Cancer
Causes Control (2003) 14(6):579–85. doi:10.1023/A:1024891201329
27. ThunMJ, Jemal A.Howmuch of the decrease in cancer death rates in theUnited
States is attributable to reductions in tobacco smoking? Tob Control (2006)
15(5):345–7. doi:10.1136/tc.2006.017749
28. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al.
50-year trends in smoking-related mortality in the United States. N Engl J Med
(2013) 368(4):351–64. doi:10.1056/NEJMsa1211127
29. Jin XM, Wu XF, Roth JA, Amos CI, King TM, Branch C, et al. Higher lung-
cancer risk for younger African-Americans with the Pro/Pro P53 genotype.
Carcinogenesis (1995) 16(9):2205–8. doi:10.1093/carcin/16.9.2205
30. Kashii T, Mizushima Y, Lima CE, Noto H, Sato H, Saito H, et al. Studies
on clinicopathological features of lung cancer patients with K-ras/p53 gene
alterations: comparison between younger and older groups. Oncology (1995)
52(3):219–25. doi:10.1159/000227461
31. Sekine I, Yokose T, Ogura T, Suzuki K, Nagai K, Kodama T, et al. Microsatellite
instability in lung cancer patients 40 years of age or younger. Jpn J Cancer Res
(1997) 88(6):559–63. doi:10.1111/j.1349-7006.1997.tb00419.x
32. Kreuzer M, Pohlabeln H, Ahrens W, Kreienbrock L, Bruske-Hohlfeld I, Jockel
KH, et al. Occupational risk factors for lung cancer among young men. Scand J
Work Environ Health (1999) 25(5):422–9. doi:10.5271/sjweh.455
33. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet
Oncol (2011) 12(4):399–408. doi:10.1016/S1470-2045(10)70126-1
34. Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, et al. Novel
germline mutation in the transmembrane domain of HER2 in familial lung
adenocarcinomas. J Natl Cancer Inst (2014) 106(1):djt338. doi:10.1093/jnci/
djt338
35. Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, et al. Concurrent
molecular alterations in tumorswith germ line epidermal growth factor receptor
T790M mutations. Clin Lung Cancer (2013) 14(4):452–6. doi:10.1016/j.cllc.
2013.01.005
36. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers – a different
disease. Nat Rev Cancer (2007) 7(10):778–90. doi:10.1038/nrc2190
37. Lee BW, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. Association of
cigarette smoking and asbestos exposure with location and histology of lung
cancer. Am J Respir Crit Care Med (1998) 157(3 Pt 1):748–55. doi:10.1164/
ajrccm.157.3.9707025
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Thomas, Chen, Yu, Jakopovic and Giaccone. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 1137
